Cell line · CVCL_HF20
Papers25
5 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 25
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Switching Spike Plasticity Shapes ACE2 Engagement Across SARS-CoV-2 Variants. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Isolation and characterization of broadly-neutralizing anti-HCMV-gB antibodies from human donors using a prefusion-stabilized HCMV gB variant. | PLoS Pathog | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Monoclonal neutralizing antibodies elicited by infection with Kaposi sarcoma-associated herpesvirus reveal critical sites of vulnerability on gH/gL. | PLoS Pathog | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combining antibody conjugates with cytotoxic and immune-stimulating payloads maximizes anti-cancer activity. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A novel method for recombinant mammalian-expressed S-HBsAg virus-like particle production for assembly status analysis and improved anti-HBs serology. | Protein Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. | Cell Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Structure and mechanisms of transport of human Asc1/CD98hc amino acid transporter. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. | J Immunother Cancer | 2022 | Its Methods give the RRID and name the line | PubMed | |
| A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Uncovering cryptic pockets in the SARS-CoV-2 spike glycoprotein. | Structure | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. | Commun Biol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. | Elife | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1. | Cell Rep Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. | Cell Rep | 2021 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 33758873 | medRxiv | 2021 | Its Methods give the RRID and name the line | PubMed | |
| SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets. | Elife | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative glycoproteomics reveals cellular substrate selectivity of the ER protein quality control sensors UGGT1 and UGGT2. | Elife | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_HF20/papers